Results from the latest phase 3 clinical trial testing combinations of immunotherapy and tyrosine-kinase inhibitors for advanced kidney cancer improve standard first-line treatment options for patients.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clinical significance and oncogenic function of NR1H4 in clear cell renal cell carcinoma
BMC Cancer Open Access 19 September 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Motzer, R.J. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2035716 (2021).
Choueiri, T. K. & Motzer, R. J. N. Engl. J. Med. 376, 354–366 (2017).
Motzer, R. J. et al. N. Engl. J. Med. 369, 722–731 (2013).
Chen, D. S. & Mellman, I. Nature 541, 321–330 (2017).
Albiges, L. et al. ESMO Open 5, e001079 (2020).
Powles, T. et al. Lancet Oncol 21, 1563–1573 (2020).
Choueiri, T. K. et al. Ann. Oncol. 31, 1030–1039 (2020).
Choueiri, T. K. et al. N. Engl. J. Med 384, 829–841 (2021).
Pal, S. K. et al. Lancet 397, 695–703 (2021).
Pal, S. K. et al. BMC Cancer 19, 548 (2019).
Cho, H. et al. Nature 539, 107–111 (2016).
Chen, W. et al. Nature 539, 112–117 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
T.Z. has received research funding (to Duke) from Pfizer, Janssen, Acerta, Abbvie, Novartis, Merrimack, OmniSeq, PGDx, Merck, Mirati, Astellas and Regeneron; has received consulting/speaking fees from Genentech Roche, Exelixis, Genomic Health and Sanofi Aventis; reports serving on an advisory board and/or consulting for AstraZeneca, Bayer, Pfizer, Foundation Medicine, Janssen, Amgen, MJH Associates, Merck, BMS, Pharmacyclics, Seattle Genetics, Calithera and Dendreon; and reports stock ownership and/or employment (spouse) with Capio Biosciences and Archimmune Therapeutics. D.J.G. has received research support (to Duke) from Acerta, Astellas, BMS, Bayer, Calithera, Exelixis, Janssen, Myovant, Pfizer, Novartis and Sanofi Aventis; and consulting fees from Vizuri Health sciences, UroToday, Sanofi, Pfizer, Nektar, Myovant, Modra, Merck, Ipsen, Flatiron, Exelixis, Capio, EMD Serono, BMS, Bayer, AstraZeneca and Astellas.
Rights and permissions
About this article
Cite this article
Zhang, T., George, D.J. Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment. Nat Med 27, 586–588 (2021). https://doi.org/10.1038/s41591-021-01320-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-021-01320-x